• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    35 Stocks Moving In Monday's Mid-Day Session

    1/3/22 12:06:05 PM ET
    $AFI
    $AGE
    $APLT
    $ASRT
    Building Products
    Capital Goods
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFI alert in real time by email

    Gainers

    • Immix Biopharma, Inc. (NASDAQ:IMMX) shares climbed 110.3% to $7.32. The FDA granted Rare Pediatric Disease (RPD) designation to newly listed Immix Biopharma's IMX-110 for rhabdomyosarcoma, a form of pediatric cancer.
    • Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) gained 48.6% to $3.2850. The stock may be seeing increased interested from retail investors.
    • Pear Therapeutics, Inc. (NASDAQ:PEAR) shares climbed 34.7% to $8.35. BTIG initiated coverage on Pear Therapeutics with a Buy rating and announced a price target of $12.
    • Armstrong Flooring, Inc. (NYSE:AFI) rose 25.3% to $2.48 as the company said it received $35 million capital infusion, and announced process for sale of company and consideration of other strategic alternatives.
    • Nuverra Environmental Solutions, Inc. (NASDAQ:NES) gained 24% to $3.7696.
    • Applied UV, Inc. (NASDAQ:AUVI) surged 17.7% to $3.18. Applied UV recently announced closing of $8.0 million underwritten public offering.
    • Jowell Global Ltd. (NASDAQ:JWEL) gained 16.9% to $25.20.
    • Gilat Satellite Networks Ltd. (NASDAQ:GILT) gained 15.6% to $8.17 as the company said one of the world’s largest Mobile Network Operators will deploy 4G cellular backhaul over satellite technology from Gilat..
    • BlueCity Holdings Limited (NASDAQ:BLCT) rose 15.7% to $1.77 after the company announced it received an acquisition offer for the company at $3.70 per share.
    • Nam Tai Property Inc. (NYSE:NTP) gained 15.5% to $11.65.
    • Assertio Holdings, Inc. (NASDAQ:ASRT) jumped 14.2% to $2.49.
    • Orbsat Corp. (NASDAQ:OSAT) surged 13.7% to $3.6750 as the company reported a $7.2 million private placement.
    • Theravance Biopharma, Inc. (NASDAQ:TBPH) gained 13.1% to $12.50.
    • Uranium Energy Corp. (NYSE:UEC) rose 12.8% to $3.78. Uranium Energy, last month, posted a Q1 loss of $0.01 per share.
    • Immunic, Inc. (NASDAQ:IMUX) gained 12.7% to $10.78.
    • Uranium Royalty Corp. (NASDAQ:UROY) surged 12.7% to $4.1142.
    • Signet Jewelers Limited (NYSE:SIG) gained 11.9% to $97.43.
    • Moxian (BVI) Inc (NASDAQ:MOXC) jumped 11.8% to $3.20.
    • Groupon, Inc. (NASDAQ:GRPN) shares rose 10.7% to $25.64.
    • Gevo, Inc. (NASDAQ:GEVO) gained 10% to $4.71.
    • Tesla, Inc. (NASDAQ:TSLA) jumped 9% to $1,152.02 as the company reported record quarterly and annual deliveries that exceeded the most optimistic Wall Street forecasts.
    • Frontline Ltd. (NYSE:FRO) rose 7.2% to $7.58. Frontline, in November, reported third-quarter operating revenue of $171.8 million, a decline of 30.6% year-over-year.

    Check out these big penny stock gainers and losers

    Losers

    • uCloudlink Group Inc. (NASDAQ:UCL) fell 28.7% to $4.70 after climbing 32% on Friday.
    • Applied Therapeutics, Inc. (NASDAQ:APLT) shares dipped 28.3% to $6.42. Following discussions with the FDA, Applied Therapeutics decided to hold on submitting a marketing application for AT-007 for Galactosemia pending additional talks with the agency.
    • AgeX Therapeutics, Inc. (NASDAQ:AGE) fell 16.1% to $0.9151 after jumping 85% on Friday. AgeX Therapeutics recently announced plans to collaborate with University of California, Irvine, on research program for exosome-based therapies for certain brain disorders.
    • CNH Industrial N.V. (NYSE:CNHI) shares fell 13.9% to $16.73. CNH Industrial NV and Iveco Group executed the deed of demerger whereby, effective January 1, 2022, the relevant Iveco Group business segments separated from CNH Industrial.
    • Himax Technologies, Inc. (NASDAQ:HIMX) fell 12% to $14.07.
    • Heliogen, Inc. (NASDAQ:HLGN) dropped 11.7% to $13.70 after jumping around 62% on Friday.
    • Fathom Digital Manufacturing Corporation (NYSE:FATH) dropped 11.1% to $7.04 after surging 22% on Friday.
    • Nutriband Inc. (NASDAQ:NTRB) fell 9.9% to $9.08. Nutriband shares climbed 158% on Friday after the company announced the Korean Intellectual Property Office has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the company's lead technology AVERSA.
    • Medalist Diversified REIT, Inc. (NASDAQ:MDRR) shares fell 8.8% to $1.0950. Medalist Diversified REIT shares jumped around 18% on Friday after the company announced a stock repurchase program of 500,000 shares.
    • MongoDB, Inc. (NASDAQ:MDB) fell 8% to $486.97.
    • SuperCom Ltd (NASDAQ:SPCB) fell 7.6% to $0.5126 after declining around 9% on Friday.
    • Moderna, Inc. (NASDAQ:MRNA) declined 7.1% to $235.85. Moderna recently announced supply agreement with South Korea for additional 20 million doses of its COVID-19 vaccine or updated booster candidate in 2022.
    • Kingsoft Cloud Holdings Limited (NASDAQ:KC) dropped 7% to $14.70. Goldman Sachs downgraded Kingsoft Cloud from Buy to Neutral and lowered the price target from $37 to $18.
    Get the next $AFI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFI
    $AGE
    $APLT
    $ASRT

    CompanyDatePrice TargetRatingAnalyst
    Immix Biopharma Inc.
    $IMMX
    2/9/2026$14.00Outperform
    Mizuho
    Himax Technologies Inc.
    $HIMX
    2/4/2026$8.00Overweight → Equal-Weight
    Morgan Stanley
    Tesla Inc.
    $TSLA
    1/30/2026$150.00 → $145.00Underweight
    Analyst
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Tesla Inc.
    $TSLA
    1/12/2026$120.00 → $130.00Underweight
    Wells Fargo
    Frontline Plc
    $FRO
    1/12/2026Neutral → Buy
    Clarksons Platou
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    MongoDB Inc.
    $MDB
    1/6/2026$480.00 → $500.00Buy
    Needham
    More analyst ratings

    $AFI
    $AGE
    $APLT
    $ASRT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anfield Energy Announces Special Shareholder Meeting and Mailing of Related Documents

    VANCOUVER, British Columbia, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Anfield Energy Inc. (TSX.V: AEC, NASDAQ:AEC, FRANKFURT: 0AD) ("Anfield" or the "Company") announces that today is the legal mailing date for the mailing and filing of the notice of a meeting of shareholders, the management information circular, and related documents (collectively, the "Meeting Materials") to convene a special meeting (the "Meeting") of shareholders. The Meeting will take place on February 27, 2026 at 10:00 AM (Vancouver Time). Copies of the Meeting Materials are available for review under the profile for the Company on SEDAR+ (www.sedarplus.ca) and on Anfield's corporate website (https://anfieldenergy.com). Th

    2/6/26 4:30:00 PM ET
    $AEC
    $UEC
    Metal Mining
    Basic Materials
    Other Metals and Minerals

    The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

    VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad chemotherapy and toward precision biologics like mRNA and oncolytic viruses. The FDA is actively accelerating this cycle, having granted multiple breakthrough designations in January 2026 alone for platforms that demonstrate genuine survival durability[2]. This structural realignment positions Oncolytics Biotech Inc. (NASDAQ:ONCY), Moderna (NASDAQ:MRNA), Immunome (NASDAQ:IMNM), Autolus Therapeutics (NASDAQ:AUTL), and Prelude Therapeutics (NASDAQ:PRLD) within the emerging biological innovation c

    2/5/26 9:26:03 AM ET
    $AUTL
    $IMNM
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Verity and Bushel Announce Integration to Advance Traceable Agricultural Practices Across the Supply Chain

    ENGLEWOOD, Colo. and FARGO, N.D., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Verity Holdings, LLC, a wholly owned subsidiary of Gevo, Inc. (NASDAQ:GEVO), and Bushel today announced an integration that will connect Bushel's on-farm data with Verity's sustainability modeling and compliance platform. This integration supports the traceability and documentation of agricultural production practices that can influence carbon intensity outcomes and increase credit value under Section 45Z. It also helps position the agricultural supply chain for evolving carbon programs and market-based opportunities for traceable grain. The integration will give agribusinesses and producers a clearer path to participate

    2/4/26 5:10:14 PM ET
    $GEVO
    Major Chemicals
    Industrials

    $AFI
    $AGE
    $APLT
    $ASRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, CEO & PRESIDENT Kavanaugh Frank bought $33,541 worth of shares (2,582 units at $12.99), increasing direct ownership by 0.86% to 302,177 units (SEC Form 4)

    4 - Medalist Diversified REIT, Inc. (0001654595) (Issuer)

    12/15/25 8:53:49 AM ET
    $MDRR
    Real Estate Investment Trusts
    Real Estate

    CHAIRMAN, CEO & PRESIDENT Kavanaugh Frank bought $1,030,000 worth of shares (70,000 units at $14.71), increasing direct ownership by 30% to 299,595 units (SEC Form 4)

    4 - Medalist Diversified REIT, Inc. (0001654595) (Issuer)

    12/11/25 4:15:06 PM ET
    $MDRR
    Real Estate Investment Trusts
    Real Estate

    CHIEF FINANCIAL OFFICER Winn Charles Brent Jr. bought $5,062 worth of shares (400 units at $12.66), increasing direct ownership by 0.73% to 55,202 units (SEC Form 4)

    4 - Medalist Diversified REIT, Inc. (0001654595) (Issuer)

    12/11/25 8:11:54 AM ET
    $MDRR
    Real Estate Investment Trusts
    Real Estate

    $AFI
    $AGE
    $APLT
    $ASRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Killalea Peter Thomas exercised 30,000 shares at a strike of $6.50, increasing direct ownership by 93% to 62,293 units (SEC Form 4)

    4 - MongoDB, Inc. (0001441816) (Issuer)

    2/6/26 1:59:45 PM ET
    $MDB
    Computer Software: Prepackaged Software
    Technology

    Director Merriman Dwight A sold $440,002 worth of shares (1,190 units at $369.75) (SEC Form 4)

    4 - MongoDB, Inc. (0001441816) (Issuer)

    2/4/26 4:27:20 PM ET
    $MDB
    Computer Software: Prepackaged Software
    Technology

    Director Kanter Stacy J. returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Applied Therapeutics, Inc. (0001697532) (Issuer)

    2/4/26 11:17:54 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFI
    $AGE
    $APLT
    $ASRT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AFI
    $AGE
    $APLT
    $ASRT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.

    SCHEDULE 13G/A - Moderna, Inc. (0001682852) (Subject)

    2/9/26 10:48:12 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Applied Therapeutics Inc.

    EFFECT - Applied Therapeutics, Inc. (0001697532) (Filer)

    2/9/26 12:15:09 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Applied Therapeutics Inc.

    EFFECT - Applied Therapeutics, Inc. (0001697532) (Filer)

    2/9/26 12:15:13 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFI
    $AGE
    $APLT
    $ASRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Immix Biopharma with a new price target

    Mizuho initiated coverage of Immix Biopharma with a rating of Outperform and set a new price target of $14.00

    2/9/26 7:01:42 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Himax Tech downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Himax Tech from Overweight to Equal-Weight and set a new price target of $8.00

    2/4/26 8:28:23 AM ET
    $HIMX
    Semiconductors
    Technology

    Analyst reiterated coverage on Tesla with a new price target

    Analyst reiterated coverage of Tesla with a rating of Underweight and set a new price target of $145.00 from $150.00 previously

    1/30/26 8:00:23 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $AFI
    $AGE
    $APLT
    $ASRT
    Financials

    Live finance-specific insights

    View All

    MongoDB, Inc. Announces Date of Fourth Quarter and Full Fiscal 2026 Earnings Call

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- MongoDB, Inc. (NASDAQ:MDB) will report its fourth quarter and full fiscal year 2026 financial results for the three months ended January 31, 2026, after the U.S. financial markets close on Monday, March 2, 2026. In conjunction with this announcement, MongoDB will host a conference call on Monday, March 2, 2026, at 5:00 p.m. (Eastern Time) to discuss the Company's financial results and business outlook. A live webcast of the call will be available on the "Investor Relations" page of the Company's website at http://investors.mongodb.com. To

    2/4/26 4:05:00 PM ET
    $MDB
    Computer Software: Prepackaged Software
    Technology

    Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics

    Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ:APLT, "Applied")), a clinical-stage biopharmaceutical company. Applied's lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), for which there are currently no FDA approved treatment options available. "Cycle was founded with a commitment to support patients livi

    2/3/26 8:39:00 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gilat to Report Fourth Quarter and Full Year 2025 Results on Tuesday, February 10

    PETAH TIKVA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ:GILT, TASE: GILT)), a worldwide leader in satellite networking technology, solutions and services, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026. Conference Call and Webcast Following the release, Adi Sfadia, Chief Executive Officer, and Gil Benyamini, Chief Financial Officer, will discuss Gilat's fourth quarter 2025 results and business achievements and participate in a question and answer session: In English: Date:Tuesday, February 10, 2026Start:08:30 AM EST / 15:30 IST   A simultaneous webcast of the conference call w

    1/22/26 7:05:19 AM ET
    $GILT
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $AFI
    $AGE
    $APLT
    $ASRT
    Leadership Updates

    Live Leadership Updates

    View All

    Gevo Strengthens Operational Leadership Amid Ongoing Growth and Succession Planning

    ENGLEWOOD, Colo., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO), a leader in renewable fuels and chemicals, and carbon management, today announced the addition of agricultural industry veteran Greg Hanselman as executive vice president, operations and engineering. Mr. Hanselman's hire is part of Gevo's ongoing growth and succession planning, as Chris Ryan, Gevo's long-time chief operating officer, is planning to retire from the company in June of 2026. Mr. Hanselman comes to Gevo from previous roles in global agribusiness leadership as vice president of global engineering for Ingredion (NYSE:INGR), and as senior vice president of global manufacturing for Tate & Lyle, both lea

    1/5/26 9:00:00 AM ET
    $GEVO
    $INGR
    Major Chemicals
    Industrials
    Packaged Foods
    Consumer Staples

    Gevo Names Paul Bloom as Incoming CEO to Succeed Long-Time Leader Patrick Gruber Who Will Retire on April 1, 2026

    ENGLEWOOD, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO), a leader in renewable fuel and chemicals, and carbon management, today announced a strategic leadership transition designed to position the company for continued growth and innovation. Effective December 9, 2025, Dr. Paul Bloom has been appointed President of Gevo, Inc. and a director on Gevo's Board of Directors. Gevo's long-standing Chief Executive Officer and board member, Dr. Patrick Gruber, has assumed the role of Executive Chair of the Board. Board Chairman William H. Baum has moved into the role of lead independent director. As part of the succession plan, Dr. Gruber will continue as Chief Executive Office

    12/15/25 9:00:00 AM ET
    $GEVO
    Major Chemicals
    Industrials

    Scientists Pointing to Hidden Power Source That Could Reshape Future of AI

    This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- MiningNewsWire: Global electricity demand is reaching a pivotal turning point. The International Energy Agency (IEA) now projects that global data-center electricity use will almost double by 2030, with AI-focused facilities increasing their consumption more than four times over the same span — a trajectory pushing power grids in the United States, China, Europe, Southeast Asia and other regions to their limits. The bottleneck is no longer data throughput or semiconductor performance; the critical constraint has become electricity it

    12/3/25 8:30:00 AM ET
    $AMZN
    $AVGO
    $META
    Catalog/Specialty Distribution
    Consumer Discretionary
    Semiconductors
    Technology

    $AFI
    $AGE
    $APLT
    $ASRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Groupon Inc.

    SC 13G - Groupon, Inc. (0001490281) (Subject)

    12/13/24 10:39:00 AM ET
    $GRPN
    Advertising
    Consumer Discretionary

    SEC Form SC 13G filed by Groupon Inc.

    SC 13G - Groupon, Inc. (0001490281) (Subject)

    12/6/24 2:12:18 PM ET
    $GRPN
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by MongoDB Inc.

    SC 13G/A - MongoDB, Inc. (0001441816) (Subject)

    11/15/24 10:35:42 AM ET
    $MDB
    Computer Software: Prepackaged Software
    Technology

    $AFI
    $AGE
    $APLT
    $ASRT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

    Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

    6/10/24 1:20:50 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care